A measured research overview of SLU-PP-332: how this pan-ERR agonist works as an exercise mimetic, what the rodent data actually shows, its pharmacokinetic limits, and why there is still no human evidence.
SLU-PP-332 arrived in the literature with a vivid framing: a compound that produces the molecular signature of endurance exercise in a sedentary animal. That description is accurate as far as it goes — and it is also where the honest discussion has to start, because the entire evidence base sits in rodents and cell culture, with no human data at all.
A category correction worth making plainly: SLU-PP-332 is not a peptide. It is a synthetic small molecule — an N-acylhydrazone (CAS 303760-60-3) — catalogued alongside research peptides because it shares their metabolic-research audience. It has no amino-acid backbone and does not behave like a peptide pharmacokinetically. Researchers treating it as one by analogy will get the handling and stability assumptions wrong.
It came out of Thomas Burris's group at Saint Louis University — hence the "SLU" prefix — as a tool compound for interrogating a family of nuclear receptors.
SLU-PP-332 is an agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ). Despite the name, these are orphan nuclear receptors that do not bind estrogen and are not part of estrogen signalling; the label is a historical artifact of sequence homology. SLU-PP-332 is a pan-agonist across all three subtypes, with its highest potency at ERRα.
ERRα is a principal transcriptional regulator of oxidative metabolism, governing gene programs for mitochondrial biogenesis, fatty-acid oxidation, and cellular respiration — the same programs endurance training upregulates. The "exercise mimetic" logic follows directly: rather than signalling through a receptor that produces exercise-like downstream effects, SLU-PP-332 engages a transcription factor that exercise itself recruits.
That was the central claim of Billon et al. (ACS Chemical Biology, 2023;18(4):756–771), which reported that SLU-PP-332 induced an acute aerobic-exercise gene program in sedentary mice, increased type IIa oxidative skeletal-muscle fibres, and enhanced exercise endurance. The important control was genetic: in mice lacking ERRα, the endurance benefit did not hold. The effect is ERRα-dependent, not a nonspecific stimulant action.
The follow-up work — Billon et al., "A Synthetic ERR Agonist Alleviates Metabolic Syndrome" (Journal of Pharmacology and Experimental Therapeutics, 2024;388(2):232–240) — tested the compound across chow-fed, diet-induced obese (DIO), and ob/ob mice at 50 mg/kg twice daily by intraperitoneal injection for up to 28 days.
The clearest result was in the DIO cohort: treated animals gained under 0.5 g of fat mass over 28 days against roughly 5 g in controls, ending approximately 12% lighter. Resting energy expenditure rose across the models, and glucose tolerance improved in the DIO mice — though notably not in chow-fed animals, which is consistent with a compound that corrects a dysregulated metabolic state rather than pushing a healthy one further.
Two details deserve emphasis: the route was intraperitoneal, not oral or subcutaneous, and the dose is high. Naive allometric scaling from mouse to human is not a valid inference from data like this.
This is the part that most secondary write-ups omit, and it is arguably the most important fact about the compound.
SLU-PP-332 has poor drug-like properties. The 2026 chemical-optimization paper from Okda et al. (International Journal of Biological Macromolecules, 355:151450) reported extremely low kinetic solubility (0.2 μM) and only moderate microsomal stability (t½ ≈ 31.3 min), and framed the entire study around the resulting "need for structural optimization." In the earlier work, plasma and muscle exposure six hours after a 30 mg/kg intraperitoneal dose measured just 0.2 μM and 0.6 μM respectively.
In other words: SLU-PP-332 is a tool compound. It was built to prove that ERR agonism does something interesting, and it succeeded at that — but it was not built to be a therapeutic, and the medicinal-chemistry effort has since moved toward analogues with better solubility and metabolic resilience. The likely future of this mechanism is a successor molecule, not this one.
Against the incretin peptides — semaglutide, tirzepatide, retatrutide — SLU-PP-332 is a different proposition entirely. Those act on appetite and glycemic control through gut-hormone receptors and carry large registered human trial programs. SLU-PP-332 acts on a transcriptional oxidative-metabolism program and has none.
The closer conceptual neighbour is MOTS-c, which also touches mitochondrial metabolism, by an unrelated mechanism. And like tesofensine, SLU-PP-332 is a small molecule shelved next to peptides by association rather than chemistry. It has also drawn anti-doping attention, with in-vitro metabolite work published in Drug Testing and Analysis (2026) for doping-control purposes.
The evidence for SLU-PP-332 is preclinical and mechanistically coherent, but early. As of this writing, a search of ClinicalTrials.gov returns zero registered studies: no human efficacy data, no human safety data, no human pharmacokinetic data, no established human dosing. The rodent findings are real and were produced with appropriate genetic controls — a genuine strength — but "works in mice, ERRα-dependent" and "works in people" are separated by a gap that has swallowed a great many metabolic compounds.
For handling fundamentals, see the reconstitution guide and dosing math references — noting that solubility here is a real practical constraint, not a formality.
Is SLU-PP-332 a peptide? No. It is a synthetic small molecule — an N-acylhydrazone — with no amino-acid backbone. It is commonly listed alongside research peptides because of overlapping research interest in metabolism, not because of any chemical relationship.
What does "exercise mimetic" mean here? It refers to the finding that SLU-PP-332 activates ERRα, a transcription factor that endurance exercise also recruits, producing an overlapping oxidative-metabolism gene program in sedentary mice. It describes a transcriptional resemblance in animals — not a demonstrated substitute for exercise in humans.
Has SLU-PP-332 been tested in humans? No. There are no registered clinical trials, and no published human safety, efficacy, or pharmacokinetic data.
Why do researchers describe it as a tool compound? Because its physicochemical properties are poor — very low kinetic solubility and moderate microsomal stability. It was designed to validate the ERR mechanism rather than to serve as a drug candidate, and subsequent chemistry work has focused on improved analogues.
How does it differ from GLP-1 compounds? Mechanism and evidence maturity both. Incretin agonists are peptides acting on gut-hormone receptors, with extensive human trial data. SLU-PP-332 is a small molecule acting on nuclear receptors, with rodent data only.
